<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang xml:lang>
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>Your Digest for Saturday, Oct 28, 2023 05:59 PM</title>
  <style>
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    span.underline{text-decoration: underline;}
    div.column{display: inline-block; vertical-align: top; width: 50%;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    ul.task-list{list-style: none;}
  </style>
  <style type="text/css">
:root,
::backdrop {

--sans-font: -apple-system, BlinkMacSystemFont, "Avenir Next", Avenir,
"Nimbus Sans L", Roboto, "Noto Sans", "Segoe UI", Arial, Helvetica,
"Helvetica Neue", sans-serif;
--mono-font: Consolas, Menlo, Monaco, "Andale Mono", "Ubuntu Mono", monospace;
--standard-border-radius: 5px;

--bg: #fff;
--accent-bg: #f5f7ff;
--text: #212121;
--text-light: #585858;
--border: #898EA4;
--accent: #0d47a1;
--code: #d81b60;
--preformatted: #444;
--marked: #ffdd33;
--disabled: #efefef;
}

@media (prefers-color-scheme: dark) {
:root,
::backdrop {
color-scheme: dark;
--bg: #212121;
--accent-bg: #2b2b2b;
--text: #dcdcdc;
--text-light: #ababab;
--accent: #ffb300;
--code: #f06292;
--preformatted: #ccc;
--disabled: #111;
}

img,
video {
opacity: 0.8;
}
}

*, *::before, *::after {
box-sizing: border-box;
}

textarea,
select,
input,
progress {
appearance: none;
-webkit-appearance: none;
-moz-appearance: none;
}
html {

font-family: var(--sans-font);
scroll-behavior: smooth;
}

body {
color: var(--text);
background-color: var(--bg);
font-size: 1.15rem;
line-height: 1.5;
display: grid;
grid-template-columns: 1fr min(45rem, 90%) 1fr;
margin: 0;
}
body > * {
grid-column: 2;
}

body > header {
background-color: var(--accent-bg);
border-bottom: 1px solid var(--border);
text-align: center;
padding: 0 0.5rem 2rem 0.5rem;
grid-column: 1 / -1;
}
body > header h1 {
max-width: 1200px;
margin: 1rem auto;
}
body > header p {
max-width: 40rem;
margin: 1rem auto;
}

main {
padding-top: 1.5rem;
}
body > footer {
margin-top: 4rem;
padding: 2rem 1rem 1.5rem 1rem;
color: var(--text-light);
font-size: 0.9rem;
text-align: center;
border-top: 1px solid var(--border);
}

h1 {
font-size: 3rem;
}
h2 {
font-size: 2.6rem;
margin-top: 3rem;
}
h3 {
font-size: 2rem;
margin-top: 3rem;
}
h4 {
font-size: 1.44rem;
}
h5 {
font-size: 1.15rem;
}
h6 {
font-size: 0.96rem;
}

p, h1, h2, h3, h4, h5, h6 {
overflow-wrap: break-word;
}

h1,
h2,
h3 {
line-height: 1.1;
}

@media only screen and (max-width: 720px) {
h1 {
font-size: 2.5rem;
}
h2 {
font-size: 2.1rem;
}
h3 {
font-size: 1.75rem;
}
h4 {
font-size: 1.25rem;
}
}

a,
a:visited {
color: var(--accent);
}
a:hover {
text-decoration: none;
}
button,
.button,
a.button, 
input[type="submit"],
input[type="reset"],
input[type="button"],
label[type="button"] {
border: none;
border-radius: var(--standard-border-radius);
background-color: var(--accent);
font-size: 1rem;
color: var(--bg);
padding: 0.7rem 0.9rem;
margin: 0.5rem 0;
text-decoration: none;
font-family: inherit;
line-height: normal;
}
.button[aria-disabled="true"], input:disabled,
textarea:disabled,
select:disabled,
button[disabled] {
cursor: not-allowed;
background-color: var(--disabled);
color: var(--text-light)
}
input[type="range"] {
padding: 0;
}

abbr[title] {
cursor: help;
text-decoration-line: underline;
text-decoration-style: dotted;
}
button:enabled:hover,
.button:not([aria-disabled="true"]):hover,
input[type="submit"]:enabled:hover,
input[type="reset"]:enabled:hover,
input[type="button"]:enabled:hover,
label[type="button"]:hover {
filter: brightness(1.4);
cursor: pointer;
}
.button:focus-visible,
button:focus-visible:where(:enabled),
input:enabled:focus-visible:where(
[type="submit"],
[type="reset"],
[type="button"]
) {
outline: 2px solid var(--accent);
outline-offset: 1px;
}

header > nav {
font-size: 1rem;
line-height: 2;
padding: 1rem 0 0 0;
}

header > nav ul,
header > nav ol {
align-content: space-around;
align-items: center;
display: flex;
flex-direction: row;
flex-wrap: wrap;
justify-content: center;
list-style-type: none;
margin: 0;
padding: 0;
}

header > nav ul li,
header > nav ol li {
display: inline-block;
}
header > nav a,
header > nav a:visited {
margin: 0 0.5rem 1rem 0.5rem;
border: 1px solid var(--border);
border-radius: var(--standard-border-radius);
color: var(--text);
display: inline-block;
padding: 0.1rem 1rem;
text-decoration: none;
}
header > nav a:hover,
header > nav a.current,
header > nav a[aria-current="page"] {
border-color: var(--accent);
color: var(--accent);
cursor: pointer;
}

@media only screen and (max-width: 720px) {
header > nav a {
border: none;
padding: 0;
text-decoration: underline;
line-height: 1;
}
}

aside, details, pre, progress {
background-color: var(--accent-bg);
border: 1px solid var(--border);
border-radius: var(--standard-border-radius);
margin-bottom: 1rem;
}
aside {
font-size: 1rem;
width: 30%;
padding: 0 15px;
margin-inline-start: 15px;
float: right;
}
*[dir="rtl"] aside {
float: left;
}

@media only screen and (max-width: 720px) {
aside {
width: 100%;
float: none;
margin-inline-start: 0;
}
}
article, fieldset, dialog {
border: 1px solid var(--border);
padding: 1rem;
border-radius: var(--standard-border-radius);
margin-bottom: 1rem;
}
article h2:first-child,
section h2:first-child {
margin-top: 1rem;
}
section {
border-top: 1px solid var(--border);
border-bottom: 1px solid var(--border);
padding: 2rem 1rem;
margin: 3rem 0;
}

section + section,
section:first-child {
border-top: 0;
padding-top: 0;
}
section:last-child {
border-bottom: 0;
padding-bottom: 0;
}
details {
padding: 0.7rem 1rem;
}
summary {
cursor: pointer;
font-weight: bold;
padding: 0.7rem 1rem;
margin: -0.7rem -1rem;
word-break: break-all;
}
details[open] > summary + * {
margin-top: 0;
}
details[open] > summary {
margin-bottom: 0.5rem;
}
details[open] > :last-child {
margin-bottom: 0;
}

table {
border-collapse: collapse;
margin: 1.5rem 0;
}
td,
th {
border: 1px solid var(--border);
text-align: start;
padding: 0.5rem;
}
th {
background-color: var(--accent-bg);
font-weight: bold;
}
tr:nth-child(even) {

background-color: var(--accent-bg);
}
table caption {
font-weight: bold;
margin-bottom: 0.5rem;
}

textarea,
select,
input {
font-size: inherit;
font-family: inherit;
padding: 0.5rem;
margin-bottom: 0.5rem;
color: var(--text);
background-color: var(--bg);
border: 1px solid var(--border);
border-radius: var(--standard-border-radius);
box-shadow: none;
max-width: 100%;
display: inline-block;
}
label {
display: block;
}
textarea:not([cols]) {
width: 100%;
}

select:not([multiple]) {
background-image: linear-gradient(45deg, transparent 49%, var(--text) 51%),
linear-gradient(135deg, var(--text) 51%, transparent 49%);
background-position: calc(100% - 15px), calc(100% - 10px);
background-size: 5px 5px, 5px 5px;
background-repeat: no-repeat;
padding-inline-end: 25px;
}
*[dir="rtl"] select:not([multiple]) {
background-position: 10px, 15px;
}

input[type="checkbox"],
input[type="radio"] {
vertical-align: middle;
position: relative;
width: min-content;
}
input[type="checkbox"] + label,
input[type="radio"] + label {
display: inline-block;
}
input[type="radio"] {
border-radius: 100%;
}
input[type="checkbox"]:checked,
input[type="radio"]:checked {
background-color: var(--accent);
}
input[type="checkbox"]:checked::after {

content: " ";
width: 0.18em;
height: 0.32em;
border-radius: 0;
position: absolute;
top: 0.05em;
left: 0.17em;
background-color: transparent;
border-right: solid var(--bg) 0.08em;
border-bottom: solid var(--bg) 0.08em;
font-size: 1.8em;
transform: rotate(45deg);
}
input[type="radio"]:checked::after {

content: " ";
width: 0.25em;
height: 0.25em;
border-radius: 100%;
position: absolute;
top: 0.125em;
background-color: var(--bg);
left: 0.125em;
font-size: 32px;
}

@media only screen and (max-width: 720px) {
textarea,
select,
input {
width: 100%;
}
}

input[type="color"] {
height: 2.5rem;
padding: 0.2rem;
}

input[type="file"] {
border: 0;
}

hr {
border: none;
height: 1px;
background: var(--border);
margin: 1rem auto;
}
mark {
padding: 2px 5px;
border-radius: var(--standard-border-radius);
background-color: var(--marked);
color: black;
}
img,
video {
max-width: 100%;
height: auto;
border-radius: var(--standard-border-radius);
}
figure {
margin: 0;
display: block;
overflow-x: auto;
}
figcaption {
text-align: center;
font-size: 0.9rem;
color: var(--text-light);
margin-bottom: 1rem;
}
blockquote {
margin-inline-start: 2rem;
margin-inline-end: 0;
margin-block: 2rem;
padding: 0.4rem 0.8rem;
border-inline-start: 0.35rem solid var(--accent);
color: var(--text-light);
font-style: italic;
}
cite {
font-size: 0.9rem;
color: var(--text-light);
font-style: normal;
}
dt {
color: var(--text-light);
}

code,
pre,
pre span,
kbd,
samp {
font-family: var(--mono-font);
color: var(--code);
}
kbd {
color: var(--preformatted);
border: 1px solid var(--preformatted);
border-bottom: 3px solid var(--preformatted);
border-radius: var(--standard-border-radius);
padding: 0.1rem 0.4rem;
}
pre {
padding: 1rem 1.4rem;
max-width: 100%;
overflow: auto;
color: var(--preformatted);
}

pre code {
color: var(--preformatted);
background: none;
margin: 0;
padding: 0;
}



progress {
width: 100%;
}
progress:indeterminate {
background-color: var(--accent-bg);
}
progress::-webkit-progress-bar {
border-radius: var(--standard-border-radius);
background-color: var(--accent-bg);
}
progress::-webkit-progress-value {
border-radius: var(--standard-border-radius);
background-color: var(--accent);
}
progress::-moz-progress-bar {
border-radius: var(--standard-border-radius);
background-color: var(--accent);
transition-property: width;
transition-duration: 0.3s;
}
progress:indeterminate::-moz-progress-bar {
background-color: var(--accent-bg);
}
dialog {
max-width: 40rem;
margin: auto;
}
dialog::backdrop {
background-color: var(--bg);
opacity: 0.8;
}
@media only screen and (max-width: 720px) {
dialog {
max-width: 100%;
margin: auto 1em;
}
}

.notice {
background: var(--accent-bg);
border: 2px solid var(--border);
border-radius: 5px;
padding: 1.5rem;
margin: 2rem 0;
}

strong{
color:#d81b60;
}
em {
color:#e0467e; 
}
hr
{
border: 1px;
clear: both;
display: block;
width: 100%;
height: 1px;

background-color:#686868
}
</style>
</head>
<body>
<header id="title-block-header">
<h1 class="title">Your Digest for Saturday, Oct 28, 2023 05:59 PM</h1>
</header>
<hr />
<h1 id="endocrine-regulation-of-fluid-balance-its-disorders">üîñEndocrine regulation of fluid balance it&#39;s disorders</h1>
<p>#2022BSQ-OCT/Q10<br />
3. Release of vasopressin from the <strong>hypothalamus</strong><br />
4. Direct increase of activity of <strong>Na/H antiporter</strong> -&gt; <strong>increased Na reabsorption</strong> (in the <strong>proximal</strong> tubule)</p>
<blockquote>
<p>Angiotensin I then is converted to angiotensin II in the <strong>lungs</strong> <strong>and kidneys</strong> by angiotensin-converting enzymes (ACE). Angiotensin II is an octapeptide that is activated by type-1, <strong>G protein-coupled angiotensin II receptors</strong>. These receptors have different functions depending on the types of cells that contain the receptor. <em>However, it has five primary functions that include: increasing aldosterone, increasing sodium-hydrogen exchange within the proximal renal tubule, increasing thirst drive within the hypothalamus, increasing antidiuretic hormone, and acting on G protein-coupled receptors that activate IP3/Ca2+ second messenger systems within arterioles to cause vasoconstriction</em>. Aldosterone then undergoes its actions within the kidney.</p>
</blockquote>
<h4 id="aldosterone">üìëAldosterone</h4>
<ol>
<li>Angiotensin II (mainly)</li>
</ol>
<ul>
<li>Increased sodium reabsorption by increasing ENaC expression<br />
<strong>Therefore, effect is hypervolemia, increased Sodium reabsorption, hypokalemia and metabolic alkalosis.</strong></li>
</ul>
<blockquote>
<p>Spironolactone - used to treat Conn&#39;s syndrome - is contraindicated in pregnancy because as <em>antiandrogen</em> it can cause feminization of a male foetus.<br />
+ Alpha intercalated cells - <em>Increases expression of H+ ATPase</em> -&gt; increased secretion of H+ into the lumen</p>
<ul>
<li>üìëImpaired glucose tolerance (hypokalemia inhibits insulin secretion)</li>
</ul>
</blockquote>
<h5 id="mechanism-of-hypotension-in-adrenal-crisis">Mechanism of hypotension in adrenal crisis</h5>
<ul>
<li><p>Salt wasting and dehydration</p></li>
<li><p>Glucocorticoids deficiency causes hypotension by <em>impaired vascular responsiveness to angiotensin II and norepinephrine</em>, ‚Üë prostacyclin production and ‚Üì renin substrate (?angiotensinogen) production.</p></li>
<li><p>Also, glucocorticoids are required for free water excretion which also contributes to the hyponatremia.</p></li>
<li><p>predominant symptom is <strong>shock</strong> + constitutional symptoms - fatigue, lethargy, N/V, abdominal pain.</p></li>
</ul>
<ul>
<li>Primary chronic adrenal insufficiency - weakness, malaise, anorexia, weight loss</li>
<li>Secondary or tertiary chronic adrenal insufficiency :</li>
</ul>
<hr />
<h2 id="diabetic-nephropathy">üîñDiabetic nephropathy</h2>
<p>#2022BSQ-OCT/Q15<br />
* At least <strong>two of three urine collections</strong> obtained over a three- to six-month should have <em>elevate albumin</em> for dianosis of albuminuria.<br />
<em>Microscopic haematuria can occur in DM</em>. but <strong>dysmorphic red cells</strong> is highly specific for <strong>non diabetic kidney disease</strong></p>
<blockquote>
<p>The gold standard for diagnosis of <strong>diabetic nephropathy is biopsy</strong>. But for practial reasons, when the clinical picture is suggestive, most patients with DM + kidney disease are managed as having diabetic nephropathy.<br />
1. DM -&gt; <em>somehow ‚Üë RAAS activity</em> -&gt; <strong>increased GFR</strong> -&gt; In early stages of DM: Glomerular <em>hyperfiltration</em>.<br />
3. <em>Hyperfiltration is associated with increased risk of progression of kidney function decline</em>.</p>
</blockquote>
<ol start="2">
<li>Oxidative stress and inflammation
<ol>
<li>DM -&gt; Advanced Glycation End products (<em>AGE</em>) -&gt; <strong>inflammation</strong></li>
<li>DM -&gt; Hyperglycaemia -&gt; ‚Üë activity of <strong>hexosamine pathway</strong> +<del>‚Üë RAAS acvitity -&gt;</del> <em>‚Üë TGF-Beta</em> production -&gt; <strong>fibrosis</strong> and atrophy<br />
<em>Mesangial proliferation</em> -&gt; further proliferation + matrix deposition -&gt; <strong>PAS positive</strong> <strong>kimmelstiel-Wilson</strong> bodies.</li>
</ol></li>
<li><strong>Nodular</strong> glomerular sclerosis &lt;- a pattern of sclerosis with nodules of matrix at the <em>periphery of the glomerulus</em>. AKA <strong>Kimmelstiel Wilson</strong> nodules. &lt;- Pathognomonic of DM (almost)</li>
<li>üìë‚ùó<strong>Glomerular basement membrane thickening is the first to be seen</strong>.</li>
</ol>
<ul>
<li>Efferent and afferent arteriolar <strong>hyalinosis</strong> - <strong>Deposition of plasma proteins</strong> (complement, immunoglobulins and fibrinogen) replace the smooth muscle cells of arteriole.
<ol>
<li>Target HBA1C of <strong>&lt; 7</strong> (subject to individual considerations)</li>
</ol></li>
</ul>
<ol start="5">
<li>‚ùó<em>Spironolactone can be used because it <strong>reduces albuminuria</strong></em> but risk of hyperkalemia.
<ol>
<li>üìëFinerenone causes less hyperkalemia.<br />
<strong>üìëSGLT2 inhibitors are not appropriate for use in patients with type 1 diabetes and kidney disease.</strong></li>
</ol></li>
</ol>
<hr />
<h3 id="overview-of-physiology">üîñOverview of physiology</h3>
<p>T3 binds to <em><strong>nuclear receptor</strong></em> --&gt; Exerts effects</p>
<h2 id="functions-of-thyroid-hormone">üîñFunctions of thyroid hormone</h2>
<table>
<thead>
<tr class="header">
<th>System</th>
<th>effect</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>CVS</td>
<td>Increase cardiac ouput ( increased heart rate, contractility, stroke volume)</td>
</tr>
<tr class="even">
<td>RS</td>
<td>Maintains respiratory drive</td>
</tr>
<tr class="odd">
<td>GI</td>
<td>increases motility</td>
</tr>
<tr class="even">
<td><strong>Blood</strong></td>
<td><strong>Incr. 2,3-DPG - increased oxygen unloading</strong></td>
</tr>
<tr class="odd">
<td>Muscles</td>
<td>Increase speed of muscle contraction</td>
</tr>
<tr class="even">
<td>Carbs</td>
<td>Increase gluconeogenesis, glycolysis and glycogenolysis, intestinal glucose absorption, cellular glucose reabsorption, but &#39;no effect on glucose level&#39; (probably because it <em>increases insulin secretion</em> )</td>
</tr>
<tr class="odd">
<td>lipid</td>
<td>Lipolysis, increased serum free fatty acids (which can be oxidised), <em>decreased</em> serum cholesterol,</td>
</tr>
<tr class="even">
<td>Lipid cont.</td>
<td>PL and TGL + increased cholesterol turnover (patients lose weight), increased liver LDL receptors (see below)</td>
</tr>
<tr class="odd">
<td>Proteins</td>
<td>Anabolism <a href="https://www.ncbi.nlm.nih.gov/books/NBK500006/">Source</a> but at high doses, catabolism.</td>
</tr>
<tr class="even">
<td>Sympathetic NS</td>
<td>Increases expression of beta adrenergic receptors and in heart decreases alpha receptors. See Perissive effect below:</td>
</tr>
<tr class="odd">
<td>At cellular level</td>
<td>Thyroid hormones No. of mitochondria, increase activity of Na/K ATPase -&gt; thermogenesis, increaes Na and K condutivity</td>
</tr>
<tr class="even">
<td>Sexual function</td>
<td><em>hypo</em>thyroidism in women -&gt; menorrhagia or oligomenorrhea, decreased libido in men and women.</td>
</tr>
</tbody>
</table>
<pre><code>- It increases rate of depolarization, repolarization and *decreases duration of action potentials*. Probably increases dromotropy as well. Effects are probably mediated by increased expression of Na/K ATPase and increased ion permeability. [Source](https://academic.oup.com/edrv/article/26/5/704/2355198) &lt;- super detailed, don&#39;t read. ;) 
</code></pre>
<ul>
<li>In hyperthyroidism, there is <em>widened pulse pressure</em>. (contributed to be <em>decreased</em> peripheral resistance). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558494/">Source</a></li>
<li>To emphasize the effect on lipid metabolism, <em>hypo</em>thyroidism causes <em>hypercholesterolemia</em>.</li>
<li><em>Thyroid hormone (and hyperthyroidism) increases hepatic LDL receptors which</em> promotes biliary excretion of cholesterol (leading to lower cholesterol levels)</li>
</ul>
<h2 id="investigation-of-thyroid-function">üîñInvestigation of thyroid function</h2>
<p>üìë<strong>Low TSH</strong> usually means hyperthyroidism <strong>except in</strong><br />
üìë<strong>High TSH + High fT4</strong> = TSHOma (rare) or Thyroid hormone resistance.<br />
For this situation, administration of TRH (TRH test) will stimulate further TSH release only in thyroid hormone resistance (<em>TSHOma is autonomic</em> and not controlled by TRH)</p>
<blockquote>
<p><strong>Thyroid peroxidase</strong> ‚Äì TPO catalyzes the iodination of tyrosine¬†residues of Tg to form monoiodotyrosine and diiodotyrosine. Nearly all patients with ‚ùó<strong>Hashimoto&#39;s thyroiditis</strong> have high serum concentrations of ‚ùóTPO antibodies.</p>
</blockquote>
<h2 id="hyperthyroidism">üîñHyperthyroidism</h2>
<ul>
<li>Autoimmunity -&gt; TSH-Receptor antibodies (thyrotropin receptor or TRAb) stimulate thyroid gland to make thyroid hormones. -&gt; <em>diffuse, <strong>non tender</strong>, goiter</em>. (MCQ Point: TSH receptor <em>inhibiting antibodies are also formed</em>)</li>
<li>Histology: Diffuse, <strong>hyperplasia and hypertrophy</strong>; follicular cells become tall and columnar with crowding and formation of papillae with no neovascularization. üìëT cell infiltrates are present within thyroid.</li>
<li><em>Orbitopathy</em> and <em>pretibial myxoedema</em> are not related to thyroxine levels. Pretibial myxoedema is caused by deposition of <strong>glycosaminoglycans</strong> and <strong>T cell infiltration</strong>.</li>
</ul>
<blockquote>
<p><strong>Ophthalmopathy</strong> is characterized by inflammation of the extraocular muscles and orbital fat and connective tissue, which results in proptosis (<strong>exophthalmos</strong>), <strong>impairment of eye muscle function</strong>, and <strong>periorbital edema</strong>.<br />
Volume of retro-orbital tissue is increased by <strong>1)</strong> <em>T cell infiltration</em>, <strong>2)</strong> <em>Inflammatory oedema</em>, <strong>3)</strong> <em>Increased extracellular matrix deposition</em>, <strong>4)</strong> <em>increased adipocytes</em>.<br />
As above, lid <em>retraction is more suggestive of Grave&#39;s ophthalmopathy</em>.</p>
</blockquote>
<h3 id="management-of-hyperthyroidism">üîñManagement of hyperthyroidism</h3>
<p>üìëBoth inhibit <strong>thyroid peroxidase</strong> which inhibits iodination of tyrosine residues on thyroglobulin.<br />
| Less severe side effects. <em>Usually first line choice</em> | Usually second line, <strong>except T1 of pregnancy</strong>, &lt;- <strong>preferred in T1</strong> <br>and thyroid storm |</p>
<hr />
<p>#2022BSQ-NOV/Q32<br />
#2022BSQ-OCT/Q1</p>
<hr />
<h1 id="cell-injury">üîñCell injury</h1>
<h2 id="overview-of-cell-injury">üîñOverview of cell injury</h2>
<p>#2022BSQ-OCT/Q12</p>
<h1 id="overview-of-types-of-necrosis">üîñOverview of types of necrosis</h1>
<pre><code>- Characteristic of *infarcts of solid organs*; the insult disrupts digestive proteins as well so that tissue architecture is preserved for *days to weeks* until phagocytic leukocytes migrate in and digest the debris.
- Occurs at the *site of an infection*. But hypoxic insult in the CNS also causes liquefactive necrosis. 
</code></pre>
<ul>
<li>Caseous necrosis:
<ul>
<li>Cheese like; <strong>characteristic of TB infection</strong>. The necrotic mass is friable, like cheese. Cellular architecture is not preserved, unlike coagulative necrosis. Often surrounded by an inflammatory border.</li>
<li>This lady knows what is looks like.--&gt; ;) <a href="https://youtu.be/eYpW9m-AB1A?t=6">Source:Video</a></li>
</ul></li>
</ul>
<h1 id="tay-sachs-disease">üîñTay Sach&#39;s disease</h1>
<hr />
<p>#2022BSQ-NOV/Q56</p>
<hr />
<p>#2022BSQ-OCT/Q04<br />
üìë<em>DMARDs takes months to act</em>.<br />
‚ùó<br />
üîñ</p>
<hr />
<h1 id="neurocysticercosis">üîñNeurocysticercosis</h1>
<p>#2022BSQ-OCT/Q5</p>
<blockquote>
<p>[!TIP] Mnemonic :&quot;Solium polium&quot; - solium = pork tapeworm.<br />
Only pork tape worm causes cysticercosis<br />
üìë<strong>ONLY TAENIA SOLIUM</strong> causes <strong>CYSTICERCOSIS</strong>.<br />
Pigs are the usual intermediate host, üîñHumans are the definitive host.<br />
cysticercosis results <em>from humans acting as üîñaccidental intermediate hosts</em> for the parasite<br />
- Live cysts: Antihelminthing treatment must be <em>combined with steroid which penetrates the BBB (Dexamethasone)</em> to lessen the inflammatory response elicited following death of the parasite.<br />
- üîñPraziquental and albendazole.</p>
</blockquote>
<h1 id="granuloma-formation-and-patterns">üîñGranuloma formation and patterns</h1>
<blockquote>
<ol>
<li><em>Epithelialization</em> : where the cell membranes begin to <em>interdigitate</em>.</li>
<li><em>Giant cell</em> formation.</li>
<li>This is when <em>multiple macrophages fuse</em> to form a giant cell with multiple nuclei.<br />
Specially, <em>Th cells</em> have a significant role to play here.<br />
The pattern of inflammation can be classified in many ways. (necrotizing or not / Suppurative or not etc.)<br />
- eg <strong>Tuberculous</strong> and other <strong>infectious granulomas</strong> (fungal ones where the pathogen is intracellular). <a href="https://www.annualreviews.org/doi/10.1146/annurev-immunol-032712-100022">Source</a><br />
- Other examples of <strong>necrotizing granulomas</strong>: <strong>rheumatoid nodules</strong> and <strong>granulomatosis with polyangiitis</strong> and <del>occasionally those in <strong>sarcoidosis</strong></del>.<br />
| Cat Scratch disease | Rounded or <strong>stellate</strong>, central debris present. |<br />
| Syphillitic gumma | <strong>Central necrosis</strong> but with preserved cell outlines, <em>plasma cell</em> infiltrate |</li>
</ol>
</blockquote>
<h2 id="granulomatous-diseases">üîñGranulomatous diseases</h2>
<h1 id="pyoderma-gangrenosum">üîñPyoderma gangrenosum</h1>
<ul>
<li><strong>Rheumatoid arthritis</strong></li>
<li><strong>Ulcerative colitis</strong> and Chron&#39;s (to a lesser extent)<br />
#2022BSQ-OCT/Q2</li>
</ul>
<ol>
<li>Seeding of body cavities : Typical of <strong>ovarian CA</strong></li>
<li>‚ùóLymphatic spread : more typical or <strong>carcinoma</strong>
<ol>
<li>Arteries are <em>less easily penetrated than veins</em>. ‚ùóMets occur along venous drainage.</li>
<li>All portal drainage goes to the liver; all caval blood flows to the lung -&gt; these capillary beds are the main sites of metastasis in ‚ùóhaematogenous metastasis.</li>
</ol></li>
<li>‚ùóThyroid and prostate CA metastasize via the paravertebral plexus -&gt; vertebral metastases.
<ol>
<li>bone metastases are more frequent in <em>follicular</em> and <em>medullary</em> thyroid cancers</li>
</ol></li>
<li>‚ùóRenal and hepatic CA like to grown inside veins:
<ol>
<li>‚ùóRenal - <em>renal veins</em> and IVC</li>
<li>‚ùóLiver <em>hepatic veins</em> and IVC</li>
</ol></li>
<li>Path of venous drainage alone doesn&#39;t account for the distribution of particular metastatic tumours; Some tumours have a propensity to metastasize to particular organs. This may be due to <em>chemoattraction</em> or expression of tissue specific adhesion molelcules by tumour cells.
<ol>
<li>‚ùó<strong>prostatic</strong> carcinoma preferentially spreads to <strong>bone</strong>,</li>
<li>‚ùó<strong>bronchogenic</strong> carcinomas tend to involve the <em><strong>adrenals</strong></em></li>
<li>and the brain, and <strong>neuroblastomas</strong> spread to the <em>liver</em> and <em><strong>bones</strong></em>.</li>
</ol></li>
</ol>
<h3 id="brain-tumours">üîñBrain tumours</h3>
<h1 id="atherosclerosis">üîñAtherosclerosis</h1>
<p>#2022BSQ-OCT/Q08</p>
<h2 id="selected-gastrointestinal-regulatory-peptides">üîñSelected gastrointestinal regulatory peptides</h2>
<p>#2022BSQ-OCT/Q24<br />
<em>Vasoactive intestinal peptide (VIP)</em> -&gt; Secreted by enteric <strong>NERVES</strong> -&gt; Neurotransmitter, Stimulates insulin release, splanchnic vasodildation and intestinal secretion of water and electrolytes; also <em>relaxes smooth muscles</em>, including the lower esophageal sphincter and colon<br />
Mnemonic: VIP readies the stomach and gut receival of food.</p>
<p><em>Glucose dependent insulinotropic polypeptide</em> - <strong>GIP</strong> - - From duodenum, gastric antrum and ileum - stimulated by <em>intraduodenal</em> glucose -&gt; <strong>incretin</strong> effect. (produced by K cells)<br />
<em>GLP-1</em> - The main actions of GLP-1 are to <em>stimulate insulin secretion</em> (i.e., to act as an <strong>incretin</strong> hormone) and to <em>inhibit glucagon secretion</em>, to limit postprandial glucose rise. Secreted by <strong>L cells in the ileum and colon</strong>.</p>
<blockquote>
<p>[!TIP] Mnemonic: All of these hormones generally cause changes which promote digestion and absorption except for <em>somatostatin</em><br />
<strong>Somatostatin</strong>: somatostatin decreases endocrine and exocrine secretion and blood flow, <em>reduces gastrointestinal motility</em> and <em>gallbladder contraction, and inhibits secretion of most gastrointestinal hormones</em>.</p>
</blockquote>
<p>Secretin: physiologic role increases pancreatic bicarbonate secretion and inhibits gastrin production. But in gastric CA, administration of secretin causes <em>increased</em> gastrin production. (paradoxically)</p>
<h1 id="bilirubin-physiology-and-elevations">üîñBilirubin physiology and elevations</h1>
<blockquote>
<p>The transport proteins requried for reabsorption are affected in <strong>Rotor syndrome</strong> -&gt; leads to conjugated and unconjugated hyperbilirubinaemia.(mostly conjugated)<br />
?? are the only causes of unconjugated hyperbiliribunaemia CN , Gilbert and haemolytic anaemias?<br />
1. It&#39;s possible in cirrhosis but usually, &quot;<em>conjugation is better preserved than other aspects of bilirubin metabolism like canalicular secretion</em>&quot;.<br />
2. <strong>Gentamicin</strong> can inhibit UGT1A1 -&gt; <em>unconjugated hyperbilirubinaemia</em></p>
</blockquote>
<hr />
<pre><code>3. **Gastrin** from **G cells** in the ***antrum of the pylorus***  stimulates *histamine* release from ECL cells (fundic glands)-&gt; *histamine* stimulates acid secretion from parietal cells
1. Somatostatin - **potent anti acid hormone**. Secreted by ***D cells*** located throughout gastric mucosa and from *oxyntic glands.* It inhibits histamine release -&gt; *reduces parietal cell acid production*.
</code></pre>
<hr />
<p>#2022BSQ-OCT/Q07<br />
Strongly associated with <em>C. difficile infection</em>. Therefore, use should be minimized.</p>
<hr />
<h1 id="the-final-push-">The final push üí™üèº</h1>
<h2 id="main-goals">Main goals</h2>
<p>Finish reading the notes.<br />
Finish reviewing all your images.<br />
Do some Anki<br />
Review the daily digests.<br />
2018 GM question paper</p>
<h2 id="markdown-notes">Markdown notes</h2>
<p>![File sizes of md Files_Histogram.png](File sizes of md Files_Histogram.png)</p>
<blockquote>
<p>[!INFO] Median size: <strong>8572 KB</strong></p>
</blockquote>
<blockquote>
<p>[!INFO] Finish 12 notes per day from large and small sections</p>
</blockquote>
<h2 id="time-allocation">Time allocation</h2>
<p>60% for reading notes<br />
20% for the images<br />
10% for the GM paper<br />
5% for anki<br />
5% for the digests</p>
<p>12 hours / day =&gt;<br />
7.2 hours for the notes<br />
2.4 hours images<br />
1.2 hours GM paper<br />
35 minutes ANKI<br />
35 minutes Digest</p>
<hr />
<ul>
<li>Terlipressin - Vasopressin analog - reduced blood flow into portal vessels and reduces portal pressure.</li>
</ul>
<h3 id="typical-histiologic-features-of-viral-hepatitis--aih">Typical histiologic features of viral hepatitis / AIH</h3>
<table>
<thead>
<tr class="header">
<th>Hep B</th>
<th>Hep C</th>
<th>Autoimmune</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Ground glass</td>
<td>Fatty change + portal lymphoid aggregates</td>
<td>Plasma cell infiltrate</td>
</tr>
</tbody>
</table>
</body>
</html>
